论文部分内容阅读
心律失常在临床上较常见,但迄今尚缺乏理想的药物。理想的抗心律失常药物需符合以下要求:(1)降低异位起搏点的自律性:(2)延长有效不应期,使异位冲动落于不应期内;(3)加快或至少不减慢传导,有利于治疗传导阻滞或折返型心律失常。此外,还要求应用方便,起效快,作用持续时间长,副作用少以及安全性大。现将国内外较新报道的抗心律失常药物及初步的临床评价介绍如下:
Arrhythmias are clinically common, but so far no ideal drugs are available. Ideal anti-arrhythmic drugs should meet the following requirements: (1) to reduce the self-discipline of ectopic pacemaker: (2) to extend the effective refractory period so that ectopic impulse falls within the refractory period; (3) to speed up or at least Does not slow down conduction, is conducive to the treatment of conduction block or reentrant arrhythmias. In addition, it also requires easy application, fast onset of action, long duration of action, few side effects, and high safety. Newly reported at home and abroad are anti-arrhythmic drugs and preliminary clinical evaluation described below: